PMID- 25823823
OWN - NLM
STAT- MEDLINE
DCOM- 20160129
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 11
DP  - 2015 Apr 20
TI  - CIP4 promotes metastasis in triple-negative breast cancer and is associated with 
      poor patient prognosis.
PG  - 9397-408
AB  - Signaling via epidermal growth factor receptor (EGFR) and Src kinase pathways 
      promote triple-negative breast cancer (TNBC) cell invasion and tumor metastasis. 
      Here, we address the role of Cdc42-interacting protein-4 (CIP4) in TNBC 
      metastasis in vivo, and profile CIP4 expression in human breast cancer patients. 
      In human TNBC cells, CIP4 knock-down (KD) led to less sustained activation of Erk 
      kinase and impaired cell motility compared to control cells. This correlated with 
      significant defects in 3D invasion of surrounding extracellular matrix by CIP4 KD 
      TNBC cells when grown as spheroid colonies. In mammary orthotopic xenograft 
      assays using both human TNBC cells (MDA-MB-231, HCC 1806) and rat MTLn3 cells, 
      CIP4 silencing had no overt effect on tumor growth, but significantly reduced the 
      incidence of lung metastases in each tumor model. In human invasive breast 
      cancers, high CIP4 levels was significantly associated with high tumor stage, 
      TNBC and HER2 subtypes, and risk of progression to metastatic disease. Together, 
      these results implicate CIP4 in promoting metastasis in TNBCs.
FAU - Cerqueira, Otto L D
AU  - Cerqueira OL
AD  - Departamento de Bioquimica, Instituto de Quimica, Universidade de Sao Paulo, Sao 
      Paulo, SP, Brazil.
FAU - Truesdell, Peter
AU  - Truesdell P
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
FAU - Baldassarre, Tomas
AU  - Baldassarre T
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
FAU - Vilella-Arias, Santiago A
AU  - Vilella-Arias SA
AD  - Departamento de Bioquimica, Instituto de Quimica, Universidade de Sao Paulo, Sao 
      Paulo, SP, Brazil.
FAU - Watt, Kathleen
AU  - Watt K
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
FAU - Meens, Jalna
AU  - Meens J
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
FAU - Chander, Harish
AU  - Chander H
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
FAU - Osorio, Cynthia A B
AU  - Osorio CA
AD  - Department of Anatomic Pathology, A.C. Camargo Hospital, Sao Paulo, SP, Brazil.
FAU - Soares, Fernando A
AU  - Soares FA
AD  - Department of Anatomic Pathology, A.C. Camargo Hospital, Sao Paulo, SP, Brazil.
AD  - Instituto Nacional de Ciencia e Tecnologia em Oncogenomica, Sao Paulo, SP, 
      Brazil.
FAU - Reis, Eduardo M
AU  - Reis EM
AD  - Departamento de Bioquimica, Instituto de Quimica, Universidade de Sao Paulo, Sao 
      Paulo, SP, Brazil.
AD  - Instituto Nacional de Ciencia e Tecnologia em Oncogenomica, Sao Paulo, SP, 
      Brazil.
FAU - Craig, Andrew W B
AU  - Craig AW
AD  - Department of Biomedical and Molecular Sciences, Queen's University, and Division 
      of Cancer Biology & Genetics, Queen's Cancer Research Institute, Kingston, ON, 
      Canada.
LA  - eng
GR  - MOP119562/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (TRIP10 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - Carcinoma, Ductal, Breast/diagnosis/genetics/mortality/pathology
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Mice
MH  - Mice, Transgenic
MH  - Microtubule-Associated Proteins/*physiology
MH  - Middle Aged
MH  - Minor Histocompatibility Antigens
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Prognosis
MH  - Rats
MH  - Triple Negative Breast Neoplasms/diagnosis/genetics/*mortality/*pathology
MH  - Xenograft Model Antitumor Assays
MH  - Young Adult
PMC - PMC4496225
OTO - NOTNLM
OT  - CIP4
OT  - metastasis
OT  - triple-negative breast cancer
EDAT- 2015/04/01 06:00
MHDA- 2016/01/30 06:00
PMCR- 2015/04/20
CRDT- 2015/04/01 06:00
PHST- 2014/10/22 00:00 [received]
PHST- 2015/02/10 00:00 [accepted]
PHST- 2015/04/01 06:00 [entrez]
PHST- 2015/04/01 06:00 [pubmed]
PHST- 2016/01/30 06:00 [medline]
PHST- 2015/04/20 00:00 [pmc-release]
AID - 3351 [pii]
AID - 10.18632/oncotarget.3351 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Apr 20;6(11):9397-408. doi: 10.18632/oncotarget.3351.